The current review of literature presents evidence supporting use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a unique pharmacologic intervention that provides such a “one-stop shop” for OSA patients because of their multiple effects on associated hypertension, diabetes mellitus, obesity, metabolic syndrome, and atherosclerotic cardiovascular diseases. The gene discussed is GLP1R; the disease is obstructive sleep apnea syndrome.